Section
This article explores the differential associations of mosaic chromosomal alterations (mCAs), especially chromosomal loss and mosaic loss of the X chromosome, with systemic sclerosis and its subtypes, revealing phenotype-specific genetic co
Factor XI-targeted antibodies, amrecibart and cenvacibart, offer promising anticoagulation by selectively inhibiting intrinsic coagulation pathways, potentially reducing thrombosis without increasing bleeding risk.
This study provides a comprehensive single-cell immune atlas of multiple myeloma, revealing dynamic tumor microenvironment ecotypes linked to disease progression, immune dysfunction, and treatment response, offering new avenues for precisio
This article reviews current strategies to identify and diagnose carriers of hemophilia and women and girls with the condition, highlighting advances in genetics and laboratory testing alongside practical clinical approaches.
The Cutaneous Lymphoma International Prognostic Index (CLIPI) enhances risk stratification and predicts progression and treatment response beyond conventional staging in advanced mycosis fungoides and Sézary syndrome.
KT-253, a selective MDM2 protein degrader, shows potent elimination of malignant myelofibrosis stem/progenitor cells by enhancing p53 pathway activation, outperforming current MDM2 inhibitors and offering a promising therapeutic advance.
Heavy menstrual bleeding in women with bleeding disorder of unknown cause requires systematic evaluation and multimodal treatment to improve outcomes and quality of life, despite diagnostic and therapeutic challenges.
This study reveals that family history significantly elevates postpartum venous thromboembolism risk in primiparous women, with risk proportional to genetic relatedness and number of affected relatives.
Telomere length serves as an independent prognostic marker for progression-free survival in chronic lymphocytic leukemia patients treated with venetoclax-based regimens, highlighting its role in risk stratification during the modern targete
A phase II trial shows that adding the bispecific antibody glofitamab to polatuzumab-R-CHP achieves a 95% complete response rate and durable remission with minimal cytokine release syndrome in high-risk diffuse large B-cell lymphoma.
This article reviews the KOMET-007 trial evaluating ziftomenib with venetoclax and azacitidine in relapsed/refractory NPM1-mutated AML, highlighting promising remission rates and manageable safety.
Lisocabtagene maraleucel shows sustained high remission rates and a favorable long-term safety profile in patients with heavily pretreated follicular lymphoma after three years of follow-up, including high-risk subgroups.
This multisite study identifies key clinical predictors including age, sex, BMI, diabetes, and prior neurotoxic treatments that contribute to chemotherapy-induced peripheral neurotoxicity (CIPN), affecting dose tolerance and long-term patie
FGF18 produced by stromal fibroblasts promotes AML progression via FGFR3-mediated AKT-mTOR signaling, forming a feed-forward loop that impairs CD8+ T-cell immunity. Neutralizing FGF18 synergizes with PD-1 blockade, suggesting a novel therap
This study demonstrates that one-stage assay (OSA) factor VIII activity better reflects the functional enhancement of AAV-derived FVIII in hemophilia A gene therapy, offering superior prediction of bleeding phenotype compared to chromogenic
This study evaluates how clonal hematopoiesis of indeterminate potential (CHIP) and pre-treatment neutropenia affect clinical outcomes and toxicities in patients undergoing CAR-T therapy for hematologic cancers, revealing nuanced risks for
Emerging therapies have revolutionized first-line treatment in large B-cell lymphoma, but inconsistent trial designs and biomarker use create complexity. Harmonized strategies integrating biomarkers, pooled data, AI, and regulatory collabor
This retrospective study evaluates survival outcomes and risk factors associated with allogeneic hematopoietic cell transplantation in young adults (18-40 years) with myelodysplastic syndrome, revealing encouraging survival rates and highli
This analysis of BMT CTN 1202 reveals that rabbit ATG exposure influences survival, relapse, and immune recovery after T-replete hematopoietic cell transplantation, advocating for model-based dosing to optimize outcomes.
This review synthesizes evidence from the ELEVATE trial on adding cusatuzumab, a CD70-targeting antibody, to venetoclax with or without azacitidine in unfit AML patients, highlighting therapeutic potential, safety concerns, and translationa
